Comparative description of the levels of matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-1 in patients with 5D stage chronic kidney disease and in patients with anterior abdominal wall hernias
https://doi.org/10.51523/2708-6011.2021-18-3-5
Abstract
Objective. To determine the levels of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the plasma of patients with 5D stage chronic kidney disease (CKD) and in patients with anterior abdominal wall hernias.
Materials and methods. Patients with end-stage chronic kidney disease and patients with anterior abdominal wall hernias were included into the study. MMP-1 and TIMP-1 plasma concentrations were determined by enzyme-linked immunosorbent assay.
Results. The analysis of the plasma of the patients with end-stage CKD and with anterior abdominal wall hernias shows a statistically significant increase in the level of MMP-1 when compared to that of the patients of the comparison group: 7.98 ng / ml and 8.35 ng / ml, respectively (p ˂ 0. 0001). The plasma level of TIMP-1 (158.85 ng / ml) was statistically significantly higher in the patients with 5D CKD than in the patients with anterior abdominal wall hernias — 33.16 ng / ml and in the comparison group — 73.46 ng / ml (p ˂ 0.001). At the same time, the TIMP-1 level was determined statistically significantly higher in the comparison group than in the patients with anterior abdominal wall hernias (p ˂ 0.001).
Conclusion. The obtained patterns may indicate an increased breakdown of type I collagen and interstitial substance in patients in the end-stage of CKD and in patients with anterior abdominal wall hernias.
Keywords
matrix metalloproteinase-1,
tissue inhibitor of matrix metalloproteinase-1,
N-telopeptide,
C-telopeptide,
collagen type 1
Supporting agencies: The study was carried out within the framework of the R&D project “To develop methods for the diagnosis and pathogenetic treatment of chronic progressive diseases of the parenchymal organs and related conditions accompanied by failed regeneration processes” under State Registration No.20190387 dated 29.03.2019.
About the Authors
V. V. Bereshchenko
Gomel State Medical University
Belarus
Belarus
Valentin V. Bereshchenko, PhD (Med), Associate Professor, Head of Department of Surgical Diseases No.3
Gomel
A. N. Lyzikov
Gomel State Medical University
Belarus
Belarus
Anatoly N. Lyzikov, DMedSc, Professor, Professor at Department of Surgical Diseases No.1 with the course of Cardiovascular Surgery
Gomel
A. N. Kondrachuk
Gomel State Medical University
Belarus
Belarus
Alexey N. Kondrachuk, senior researcher at the Research Laboratory
Gomel
References
1. Potekhina YuP. Collagen Structure and Function. Russian Osteopathic Journal. 2016;(1-2):87-99. (In Russ.). DOI: https://doi.org/10.32885/2220-0975-2016-1-2-87-99
2. Antoniou SA, Antoniou GA, Granderath FA, Simopoulos C. The role of matrix metalloproteinases in the pathogenesis of abdominal wall hernias. Eur J Clin Invest. 2009 Nov;39(11):953-959. DOI: https://doi.org/10.1111/j.1365-2362.2009.02199.x
3. Markelova EV, Zdor VV, Romanchuk AL, Birko ON. Matrix metalloproteinases: their relationship with the cytokine system, diagnostic and prognostic potential. Immunopathology, Allergology, Infectology. 2016;(2):11-22. (In Russ.). DOI: https://doi.org/10.14427/jipai.2016.2.11
4. Lee MH, Murphy G. Matrix metalloproteinases at a glance. J Cell Sci. 2004 Aug 15;117(Pt 18):4015-4016. DOI: https://doi.org/10.1242/jcs.01223
5. Shadrina AS, Plieva YaZ, Kushlinskiy DN, Morozov AA., Filipenko ML, Chang VL, Kushlinskii NE. Classification, regulation of activity, and genetic polymorphism of matrix metalloproteinases in health and disease. Almanac of Clinical Medicine. 2017;45(4):266-279. (In Russ.). DOI: https://doi.org/10.18786/2072-0505-2017-45-4-266-279
6. Gershtein ES, Mushtenko VV, Korotkova EA, Bezhanova SD, Morozov AA, Alferov AA, Kazantseva IA, Kushlinskii NE. Matrix metalloproteinases 2, 7, 8, 9 and their type 1 tissue inhibitor in serum of renal cancer patients: clinical and pathologic correlations. Almanac of Clinical Medicine. 2017;45(2):94-101. (In Russ.). DOI: https://doi.org/10.18786/2072-0505-2017-45-2-94-101
7. Ganusevich AI. The role of matrix metalloproteinases (MMPs) in malignant neoplasms. I. Characteristics of MMPs, regulation of their activity, prognostic value. Oncology. 2010;12(1):10-16. (In Russ.).
8. Henriksen NA, Yadete DH, Sorensen LT, Agren MS, Jorgensen LN. Connective tissue alteration in abdominal wall hernia. Br J Surg. 2011 Feb;98(2):210-219. DOI: https://doi.org/10.1002/bjs.7339
9. Healthcare in the Republic of Belarus [Electronic resource]: official. stat. sat. for 2018. Minsk: GU RSPC MT, 2019: 261 p. [date of access 2021 June 23]. Available from: https://belcmt.by/docs/Stat/Healthcare_in_RB_2018.pdf (In Russ.).
10. Smith CT, Katz MG, Foley D, Welch B, Leverson GE, Funk LM, Greenberg JA. Incidence and risk factors of incisional hernia formation following abdominal organ transplantation. Surg Endosc. 2015 Feb;29(2):398-404. DOI: https://doi.org/10.1007/s00464-014-3682-8
11. Varga M, Matia I, Kucera M, Oliverius M, Adamec M. Polypropylene mesh repair of incisional hernia after kidney transplantation: single-center experience and review of the literature. Ann Transplant. 2011 Jul-Sep;16(3):121-125. DOI: https://doi.org/10.12659/aot.882004
12. Nitta K, Yajima A, Tsuchiya K. Management of Osteoporosis in Chronic Kidney Disease. Intern Med. 2017 Dec 15;56(24):3271-3276. DOI: https://doi.org/10.2169/internalmedicine.8618-16
13. Lyubimova NV, Kushlinskiy NE. Biochemical markers of bone metastasis. Advances in Molecular Oncology. 2015;2(1):061-075. (In Russ.). DOI: https://doi.org/10.17650/2313-805X.2015.2.1.061-075
14. Petrova AD, Stenina MB, Manzyuk LV, Lyubimova NV, Tyulyandin SA. Time course of changes in bone resorption markers during pamidronate therapy in breast cancer patients with bone metastases. Tumors of female reproductive system. 2013;(1-2):23-27. (In Russ.). DOI: https://doi.org/10.17650/1994-4098-2013-0-1-2-23-27
Review
For citations:
Bereshchenko V.V., Lyzikov A.N., Kondrachuk A.N. Comparative description of the levels of matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-1 in patients with 5D stage chronic kidney disease and in patients with anterior abdominal wall hernias. Health and Ecology Issues. 2021;18(4):41-47. (In Russ.) https://doi.org/10.51523/2708-6011.2021-18-3-5
Views: 401
Email this article 